Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
48 participants
INTERVENTIONAL
2010-04-30
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigational influenza vaccine (FLU-v) contains multiple highly conserved T cell epitopes that are present on most influenza viruses, which have been identified as reactive in different human leukocyte antigen (HLA) populations; thus making it unlikely that anybody in the vaccinated population would be unable to mount an immune response to at least one of the epitopes contained in the vaccine.
This study will be the initial exploration of FLU-v in humans, and aims to assess the safety, tolerability, and immunogenicity in healthy subjects.
Subjects will be randomised to receive either Low Dose or High Dose FLU-v with or without adjuvant, or placebo with or without adjuvant. Twenty-four (24) subjects will be randomized to Low Dose and 24 subjects to High Dose. To mitigate risk, a staggered dosing approach will be used. One subject will receive Low Dose FLU-v without adjuvant, and one subject will receive placebo without adjuvant, followed 6 hours later by one subject receiving Low Dose FLU-v with adjuvant, and one subject receiving placebo with adjuvant. All 4 subjects will be observed overnight. At least 72 hours later and in the absence of any clinically-significant safety signals (as determined by a Safety Review Committee) the remaining 20 subjects of the Low Dose group will be dosed. If deemed appropriate by the Safety Review Committee a second sentinel cohort of 4 subjects will be observed overnight prior to completing the remaining subjects of the Low Dose group. Following a satisfactory review of safety data from the combined Low Dose cohorts, subjects in the High Dose group will be vaccinated using the same staggered dosing approach as used in Low Dose.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 2
FLU-v Low Dose with adjuvant. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.
10 subjects.
Influenza vaccine (FLU-v)
Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
Group 3
FLU-v High Dose with water for injection. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.
10 subjects.
Influenza vaccine (FLU-v)
Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
Group 4
High Dose FLU-v with adjuvant FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection. 10 subjects
Influenza vaccine (FLU-v)
Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
Group 1
FLU-v Low Dose with water for injection FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection 10 subjects
Influenza vaccine (FLU-v)
Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
Control Group
Placebo with adjuvant (4 subjects) or Placebo without adjuvant (4 subjects)
FLU-v Control
Adjuvant only or water for injection only Administration: a single subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Influenza vaccine (FLU-v)
Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
FLU-v Control
Adjuvant only or water for injection only Administration: a single subcutaneous injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must have no clinically significant abnormal findings, as judged by the Investigator, on the physical examination, ECG, medical history or clinical laboratory results during screening.
* Subject must be a non-user of tobacco products, or smoke ≤ 10 cigarettes per day (minimum 6 months prior to first dose).
* Subject must have a negative urine screen for drugs of abuse and a negative alcohol breath test at screening and check-in.
* Subject must refrain from consuming alcohol for 72 hours prior to each dose.
* Subject must be able to communicate well with the Investigator, to understand and comply with the requirements of the study, and be judged suitable for the study in the opinion of the Investigator.
* Subject must give voluntary written informed consent to participate in this trial.
Exclusion Criteria
* Subject must not have had an influenza like illness within the 3 months prior to test drug vaccination.
* Subject must not have a history or presence of significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, haematological or renal disorder.
* Subject must not have an oral temperature \>38°C on day of vaccination (otherwise subject maybe be re-assigned to a subsequent cohort).
* Subject must not suffer from an inherited or acquired immunodeficiency.
* Subject must not suffer from a disease or be undergoing treatment that can affect immune response such as systemic or high dose inhaled corticosteroids (\>800µg/day beclometasone or equivalent), radiation treatment, cytotoxic drugs or non-steroidal anti-inflammatory drugs.
* Subject must not have a serologically positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
* Subject must not have a history of severe allergic reactions and/or anaphylaxis.
* Subject must not have any arm rash or tattoos which could confound the interpretation of any injection site reactions.
* Subject must not have participated in a previous clinical trial within 90 days prior to the first vaccination.
* Subject must not have donated blood or plasma more within 90 days prior to the first vaccination.
* Subject must not have donated bone marrow within 6 months prior to the first dose.
* Subject must not have received administration of immunoglobulins and/or any blood products within 90 days prior to the first vaccination, or any planned administration during the study period.
* Subject must not use any prescription medication within 14 days prior to the first vaccination.
* Subject must not use over-the-counter (OTC) medication 7 days prior to the first vaccination. Exceptions are described below under the heading 9.4.1.
* Subject must not have received any vaccine within the 30 days prior to the first dose, and must agree not to receive any other vaccine (other than any vaccine indicated for standard of care, for example, tetanus vaccine) for the duration of this study i.e 21 days post initial FLU-v vaccination.
* Subject must not have a history of alcohol or drug abuse within 2 years prior to the first dose.
* Subject must not have any condition which, in the judgement of the Investigator, precludes inclusion into the study.
* Subjects must not donate sperm up to 90 days postdose, and those whose partner is of child-bearing potential will be advised to remain sexually inactive or use a dual method of birth control (e.g. condom together with spermicidal agent, IUD or hormonal contraception) for at least 90 days postdose.
* Subject must not be a direct employee of the study site, monitoring CRO or Sponsor.
18 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PepTcell Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
PepTcell Limited
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stuart Robinson, Dr
Role: STUDY_DIRECTOR
PepTcell Limited
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Quintiles Drug Research Unit at Guy's Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pleguezuelos O, Robinson S, Stoloff GA, Caparros-Wanderley W. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. Vaccine. 2012 Jun 29;30(31):4655-60. doi: 10.1016/j.vaccine.2012.04.089. Epub 2012 May 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FLU-v-001
Identifier Type: -
Identifier Source: org_study_id